Anagliptin is primarily used in the treatment of type 2 diabetes mellitus. It functions as a dipeptidyl peptidase-4 (DPP-4) inhibitor, which helps regulate blood sugar levels by increasing the release of insulin and decreasing the production of glucagon. This medication is often prescribed when diet, exercise, and other oral antidiabetic drugs do not adequately control blood glucose levels. It is typically administered in combination with other diabetes medications or as part of a comprehensive diabetes management plan. Anagliptin is known for its efficacy in improving glycemic control without causing significant weight gain, making it a favorable option for many patients. Additionally, it is generally well-tolerated, with a lower risk of hypoglycemia compared to some other antidiabetic agents.